These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12498153)

  • 1. The HIV pharmacy: managing quality and costs of HIV care.
    Valenti WM
    AIDS Read; 2002 Nov; 12(11):486-8. PubMed ID: 12498153
    [No Abstract]   [Full Text] [Related]  

  • 2. Providing antiretroviral therapy for HIV infection.
    Steinbrook R
    N Engl J Med; 2001 Mar; 344(11):844-6. PubMed ID: 11248164
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing total health care costs and treatment patterns of HIV patients in a managed care setting.
    Purdum AG; Johnson KA; Globe DR
    AIDS Care; 2004 Aug; 16(6):767-80. PubMed ID: 15370064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expenditures for the care of patients with HIV.
    Velasco M; Guijarro C
    N Engl J Med; 2001 Jun; 344(25):1949. PubMed ID: 11419439
    [No Abstract]   [Full Text] [Related]  

  • 6. Balancing effectiveness and access to HIV treatment in the developing world.
    Hill A; Wood E
    AIDS; 2007 Jan; 21(3):361-3. PubMed ID: 17255743
    [No Abstract]   [Full Text] [Related]  

  • 7. Study shows HAART reduced inpatient costs.
    Bozzette SA; Hellinger F
    AIDS Alert; 2001 Aug; 16(8):98, 103. PubMed ID: 11547706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
    Krentz HB; Auld MC; Gill MJ;
    CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y
    J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
    Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
    AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretrovirals in India.
    Pujari S
    Issues Med Ethics; 1998 Jan; 6(1):24-5. PubMed ID: 16267924
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drugs for antiretroviral therapy. The costs of HAART].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
    [No Abstract]   [Full Text] [Related]  

  • 13. Guidance. Guideline implementation would reduce transmission, costs.
    AIDS Policy Law; 2010 Jul; 25(8):3. PubMed ID: 20806794
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
    Krentz HB; Gill MJ
    HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost of antiretroviral drugs and influence on prescribing policies.
    Jones R; Gazzard B
    Int J STD AIDS; 2006 Aug; 17(8):499-506. PubMed ID: 16925892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustaining treatment costs: who will pay?
    Zewdie D; De Cock K; Piot P
    AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744
    [No Abstract]   [Full Text] [Related]  

  • 17. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costing implications of recent treatment interruption studies.
    Gill MJ; Krentz HB
    AIDS; 2006 Nov; 20(17):2239-40. PubMed ID: 17086069
    [No Abstract]   [Full Text] [Related]  

  • 19. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W; König HH; Schmidt JO; Kalk A
    Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E; Saba J; Muyingo S; Kahn JG
    AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.